Study of MSC-Exo on the Therapy for Intensively Ill Children
Key facts
- Who runs it
- Children's Hospital of Fudan University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Sept 2022
- Ended
- 31 Dec 2024
- Type of study
- Observational, 2 groups
- Record updated
- 15 June 2022
- Why it stopped
- Lacking of funding
Who can take part
- Age
- 29 days to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- children hospitalized in PICU of Children's Hospital of Fudan University
Who cannot take part
- discharge within 48 hours
- patients without informed consent
- incomplete clinical and demographic data
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
At present, a number of projects related to MSCs have been approved for graft-versus-host disease, myocardial infarction, Crohn's disease and other diseases, indicating a strong therapeutic potential of MSCs. However, the efficacy of MSC-Exo for severely infected children is not fully evaluated. In our study, patients who met the inclusion criteria will be divided into trial group and control group. Clinical and demographic data, as well as treatment outcome will be collected from the electronic health record. This study will evaluate the application and therapeutic effect of MSC-Exo in severely infected children, and determine the Optimal dosage and infusion.
The 2 groups in the trial
- trial group
Mesenchymal Stem Cell-Derived Exosomes
- control group
conventional treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Study of Exosomes Derived From Mesenchymal Stem Cells on the Therapy for Children With Severe Infection
- Record updated
- 15 June 2022